CL2022003725A1 - Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. - Google Patents

Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.

Info

Publication number
CL2022003725A1
CL2022003725A1 CL2022003725A CL2022003725A CL2022003725A1 CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1 CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1
Authority
CL
Chile
Prior art keywords
treatment
activity
diseases associated
aberrant
interleukin
Prior art date
Application number
CL2022003725A
Other languages
Spanish (es)
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/en
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of CL2022003725A1 publication Critical patent/CL2022003725A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a la medicina y se refiere al tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6 y el desarrollo del síndrome de liberación de citocinas (tormenta de citocinas), preferentemente el tratamiento de COVID-19, así como otras enfermedades complicadas por la actividad aberrante de interleucina-6 y el desarrollo del síndrome de liberación de citocinas, utilizando el compuesto 1-(2-(1-metil-1Himidazol-4-il)etil)piperidina-2,6-diona (fórmula I). La invención proporciona la creación de un nuevo fármaco eficaz para el tratamiento de enfermedades asociadas con el desarrollo del síndrome de liberación de citocinas.The present invention relates to medicine and concerns the treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine storm), preferably the treatment of COVID-19, as well as other diseases complicated by aberrant interleukin-6 activity and the development of cytokine release syndrome, using the compound 1-(2-(1-methyl-1Himidazol-4-yl)ethyl)piperidine-2,6-dione ( formula I). The invention provides for the creation of a new effective drug for the treatment of diseases associated with the development of cytokine release syndrome.

CL2022003725A 2020-06-26 2022-12-22 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. CL2022003725A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6

Publications (1)

Publication Number Publication Date
CL2022003725A1 true CL2022003725A1 (en) 2023-05-19

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003725A CL2022003725A1 (en) 2020-06-26 2022-12-22 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.

Country Status (6)

Country Link
CN (1) CN115803026A (en)
BR (1) BR112022026356A2 (en)
CL (1) CL2022003725A1 (en)
CO (1) CO2023000604A2 (en)
MA (1) MA58653B1 (en)
WO (1) WO2021262040A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (en) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections
WO2023249516A1 (en) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Novel crystalline form of 1-[2-(1-methylimidazole-4-yl)ethyl]perhydroazine-2,6-dione and pharmaceutical use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
DE10002509A1 (en) * 2000-01-21 2001-07-26 Gruenenthal Gmbh New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders
UA115431C2 (en) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Use of glutaryl histamine to treat respiratory tract infections
CN102432544B (en) * 2011-11-17 2014-05-21 天津医科大学 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof
BR122020010204B1 (en) * 2013-04-12 2022-03-03 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" COMPOUND DERIVED FROM GLUTARIMIDE, ITS USE, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION
RU2552929C1 (en) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
GEP20227354B (en) * 2017-09-07 2022-02-25 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2023522618A (en) * 2020-04-13 2023-05-31 ユニバーシティー ヘルス ネットワーク Methods for treating cytokine release syndrome
EP4144728A4 (en) * 2020-04-30 2023-08-23 Shanghaitech University Heterocycle and glutarimide skeleton-based compound and applications thereof

Also Published As

Publication number Publication date
RU2020121363A (en) 2021-12-27
CO2023000604A2 (en) 2023-01-26
BR112022026356A2 (en) 2023-01-17
MA58653A1 (en) 2023-07-31
CN115803026A (en) 2023-03-14
MA58653B1 (en) 2024-02-29
WO2021262040A1 (en) 2021-12-30
RU2020121363A3 (en) 2021-12-27

Similar Documents

Publication Publication Date Title
CL2022003725A1 (en) Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.
CL2022001625A1 (en) Pyrazolyl derivatives useful as anti-cancer agents
UY32462A (en) NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT
CO6960552A2 (en) Compounds of (hetero) arylcyclopropylamine as inhibitors of lsd1
AR060536A1 (en) GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS
ECSP12011638A (en) PIRIDINE AND PIRAZINE DERIVATIVES AS PROTEIN KINase MODULATORS
ECSP066302A (en) OMEGA-CARBOXIARIL-DIFENIL-UREA REPLACED WITH FLUORINE FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS
AR077975A1 (en) PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
MA37405A1 (en) Heterocyclyl compounds
ECSP088973A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3)
CO7131360A2 (en) Novel substituted cyclic n-pyridinyl amides as kinase inhibitors
UY32483A (en) NEW BENCIMIDAZOL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY SINCICIAL VIRUS
CL2015002608A1 (en) Amino-pyrazole compound and related medicinal uses.
MX2020004283A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors.
DOP2024000039A (en) QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS
RU2011138962A (en) 4-ISOPROPYLPHENYL GLUCITITE DERIVATIVES AS SGLT1 INHIBITORS
EA201071039A1 (en) NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETYLINDASOL AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 And P40
AR124688A2 (en) A PYRIMIDINE SULFONAMIDE OR A TAUTOMER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EA201001857A1 (en) PHARMACEUTICAL MEDICINE FORM FOR IMMEDIATE RELEASE OF INDOLINON DERIVATIVE
UY38144A (en) INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE
CL2011002181A1 (en) Cyclic or heterocyclic compounds (n, o, s) of phenyl (heterocyclyl) phenyl (methyl, ethyl) amine derivatives, gpr119 agonists and dpp-iv inhibitors; pharmaceutical composition; and its use for the treatment of type II diabetes, obesity, metabolic syndrome, glucose tolerance and hyperlipidemia, among other diseases.
UY30916A1 (en) DERIVATIVES OF 1- [REPLACED] - 3- [REPLACED] -1-AZONA-BICICLO [2,2,2] OCTANO AND ITS ENANTIOMERS
EA202091604A1 (en) INHIBITION OF THE ION CHANNEL A1 WITH A TRANSITOR RECEPTOR POTENTIAL
ECSP088257A (en) AMIDA DERIVATIVES
MX2020004025A (en) Epidermal growth factor receptor inhibitors.